Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Diagnos (TSE:ADK)
TSXV:ADK
Diagnos (ADK) Stock Price & Analysis
17 Followers
ADK Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$0.23 - C$0.59
Previous CloseC$0.28
Volume124.50K
Average Volume (3M)85.62K
Market Cap
C$22.68M
Enterprise ValueC$23.71M
Total Cash (Recent Filing)C$305.20K
Total Debt (Recent Filing)C$3.20M
Price to Earnings (P/E)-6.6
Beta0.37
Next Earnings
Jun 06, 2024EPS Estimate
-C$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding74,357,028
10 Day Avg. Volume52,765
30 Day Avg. Volume85,620
Standard Deviation0.22
R-Squared0.00746
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-7.10
Price to Sales (P/S)41.83
Price to Cash Flow (P/CF)N/A
P/FCF Ratio37.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$1.50Price Target Upside391.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Diagnos News
PremiumCompany Announcements
Diagnos Inc. Advances AI Healthcare Modules
PremiumCompany Announcements
DIAGNOS Inc. Showcases AI Tech at Investor ConferencePremiumCompany Announcements
Diagnos Inc Grants Stock Options to Director
PremiumPress Releases
DIAGNOS Announces Grant of Stock OptionsPremiumCompany Announcements
Diagnos Inc. Enriches Board with Ex-Premier
Bulls Say, Bears Say
Bulls Say
Growth PotentialWith strong analyst confidence in DIAGNOS Inc.'s ability to secure the Quebec RFP for AI-based screening, the company is well-positioned for a potential catalyst that could significantly impact its stock value.
Market ExpansionThe seamless integration of DIAGNOS Inc.'s FLAIRE platform with existing optometry equipment enables a broader market reach, enhancing early detection and monitoring capabilities for Diabetic Retinopathy.
Strategic PartnershipDIAGNOS Inc.'s partnership with EssilorLuxottica could revolutionize Diabetic Retinopathy screening, leveraging the AI-based FLAIRE platform across approximately 18,000 optical retail locations worldwide.
Bears Say
Expansion DelaysADK continues to experience delays in its New Look roll-out, with only 50 locations online.
Financial PerformanceFQ324 gross profit and EBITDA came in below estimates, reflecting some operational challenges.
Revenue DecreaseFQ324 revenues showed a year-over-year decrease due to the absence of one-time fees from the previous fiscal year.
---
Options Prices
Currently, No data available
---
Ownership Overview
75.93% Insiders
0.00% Mutual Funds
0.40% Other Institutional Investors
23.67% Public Companies and
Individual Investors
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.23 and its highest was C$0.59 in the past 12 months.
What is Diagnos’s market cap?
Currently, no data Available
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Jun 06, 2024 which is in 35 days.
How were Diagnos’s earnings last quarter?
Diagnos released its earnings results on Feb 28, 2024. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Undervalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate is -C$0.01.
How many shares outstanding does Diagnos have?
Diagnos has 74,357,025 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Diagnos reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
---
Diagnos Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$1.50 (391.80% Upside)
C$1.50 (391.80% Upside)
Insider Transactions
Sold Shares
Worth C$44.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.33%
Trailing 12-Months
Company Description
Diagnos
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, US, UAE, Saudi Arabia and others. The company's key revenue is derived from Canada.
---
ADK Stock 12 Months Forecast
Average Price Target
C$1.50
▲(391.80% Upside)
Technical Analysis
Best Analysts Covering ADK
1 Year
1 Year Success Rate
8/21 ratings generated profit
1 Year Average Return
+15.14%
assigned a buy rating 30 days ago
Copying Stefan Quenneville's trades and holding each position for 1 Year would result in 38.10% of your transactions generating a profit, with an average return of +15.14% per trade.
---